Intra-Cellular Therapies, Inc.is a pharmaceuticals company that develops treatments to improve the lives of individuals with neuropsychiatric and neurologic disorders.

According to the law firm press release, the lawsuit alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) as a result, Intra-Cellular Therapies’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On July 31, 2017, the Court issued an Order consolidating cases, appointing Lead Plaintiff, and approving Lead Counsel.

On September 20, 2017, Lead Plaintiffs filed a stipulation to voluntarily dismiss this action without prejudice.